Latest Medicare Coverage News

Page 1 of 5
EBR Systems delivered higher reimbursement, manufacturing and revenue milestones in the third quarter, but a sharp September slowdown and a formal going-concern warning have shifted attention to execution and funding. The company says it holds US$93.2 million in cash, cash equivalents and marketable securities, while US$41.8 million of debt falls due within 12 months.
Victor Sage
Victor Sage
10 Nov 2026
Pacific Edge has secured final Medicare coverage for Cxbladder Triage and Triage Plus in intermediate-risk microhematuria, with the policy due to take effect on 20 December. The decision gives the company a clearer reimbursement pathway, but revenue gains still depend on adoption and testing volumes.
Ada Torres
Ada Torres
6 Nov 2026
Pacific Edge has secured new US payer access and a Veterans Administration purchasing agreement while proposed Medicare price increases could materially lift revenue per test. The recovery remains unfinished, however, with US commercial volumes down 13% and final Medicare coverage still pending.
Ada Torres
Ada Torres
19 Oct 2026
Pacific Edge is positioning Cxbladder for a Medicare-led recovery, but the company remains loss-making with NZ$7.8 million in net cash after a difficult FY26. The investment case now turns on final US coverage, test volumes and whether the enlarged balance sheet can carry the business to scale.
Ada Torres
Ada Torres
14 Sept 2026
EBR Systems has secured ISO 13485 certification for its new Santa Clara manufacturing site, paving the way for a 500% increase in WiSE System production pending FDA approval expected by year-end.
Ada Torres
Ada Torres
7 Sept 2026
Pacific Edge’s draft Medicare Local Coverage Determination for its Cxbladder bladder cancer tests marks a pivotal step toward unlocking a $10.2 billion global market. Despite FY26 setbacks, the company is poised for growth with improved reimbursement prospects and strategic cost management.
Ada Torres
Ada Torres
20 Aug 2026
Anteris Technologies posted a $51.7 million loss in H1 2026 amid ramped-up R&D and clinical trial activity, supported by a $320 million capital raise and Medicare reimbursement for its DurAVR heart valve trial.
Ada Torres
Ada Torres
12 Aug 2026
EBR Systems marked a commercial milestone with over 100 WiSE CRT implants and secured purchasing agreements with three major US healthcare networks. The company is progressing toward Medicare coverage and scaling manufacturing, supported by a near-complete A$150 million capital raise.
Ada Torres
Ada Torres
12 Aug 2026
EBR Systems advanced its wireless cardiac pacing rollout in Q2 2026, completing 46 implants and signing 17 new purchasing contracts while shifting focus to deeper utilisation within existing accounts.
Ada Torres
Ada Torres
30 July 2026
Pacific Edge edges closer to Medicare reimbursement for its bladder cancer tests while its Asia Pacific operations show rising test volumes and improved margins, signaling a path toward profitability.
Ada Torres
Ada Torres
14 July 2026
Pacific Edge reported a $35.8 million loss in FY26 amid a 47% revenue drop following Medicare coverage loss, but a draft Medicare policy and $36.1 million capital raise set the stage for recovery.
Ada Torres
Ada Torres
25 June 2026
EBR Systems has secured a significant regulatory milestone as the US Centers for Medicare & Medicaid Services (CMS) initiates a National Coverage Determination (NCD) for its WiSE wireless cardiac pacing system, aiming for approval by early 2027.
Ada Torres
Ada Torres
4 June 2026

Browse the archive

Full archive